We are live on ! Find out more
SCNI

Scinai Immunotherapeutics
SCNI

4 hedge funds and large institutions have $119K invested in Scinai Immunotherapeutics in 2016 Q3 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, 1 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

33% more funds holding

Funds holding: 3 → 4 (+1)

1% more capital invested

Capital invested by funds: $118K → $119K (+$1K)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
4
Holders Change
+1
Holders Change %
+33.33%
% of All Funds
0.11%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
–
Reduced
1
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
TRCT
Tower Research Capital (TRC)
New York
+$1.82K

Top Sellers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
-$4.73K
Name Holding Trade Value Shares
Change 		Change in
Stake
VIA
1
Vantage Investment Advisors
Pennsylvania
$62K – – –
Bank of Montreal
2
Bank of Montreal
Ontario, Canada
$55K – – –
TRCT
3
Tower Research Capital (TRC)
New York
$2K +$1.82K +5 New
UBS Group
4
UBS Group
Switzerland
– -$4.73K -13 -93%

SCNI Hedge Fund Activity: Q3 2016 in Review

4 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Scinai Immunotherapeutics (SCNI) for Q3 2016, worth a combined $119K — up 0.85% from $118K a quarter earlier.

Buyers outnumbered sellers: 1 fund opened new SCNI positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 1 trimmed.

The largest buyer was Tower Research Capital (TRC), opening a new position worth an estimated $1.82K. The largest seller was UBS Group, cutting an estimated $4.73K.

  • 4 institutional investors held Scinai Immunotherapeutics (SCNI) as of Q3 2016, up from 3 in Q2 2016.
  • Funds reported $119K of Scinai Immunotherapeutics stock for Q3 2016, up 0.85% quarter-over-quarter.
  • 1 fund opened new Scinai Immunotherapeutics positions in Q3 2016 and 0 closed out, a net change of +1 holder.
  • The largest Scinai Immunotherapeutics buyer in Q3 2016 was Tower Research Capital (TRC), an estimated $1.82K added.
  • The largest Scinai Immunotherapeutics seller in Q3 2016 was UBS Group, an estimated $4.73K sold.

Based on aggregated 13F filings for Q3 2016.